Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 11.27 -0.04 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.31 | 52 Week High | $34.49 | |||
| Open | $11.31 | 52 Week Low | $20.39 | |||
| Day High | $11.58 | P/E | N/A | |||
| Day Low | $11.09 | EPS | $-3.18 | |||
| Volume | 30,290 | |||||
